Skip to main content
TipRanks
Go Ultimate75% OFF

Dingdang Health Technology Group Ltd. (9886) AI Stock Analysis

1 Followers
HK:9886

Dingdang Health Technology Group Ltd.

(HKEX:9886)

Select Model
Rating:56Neutral
Price Target:HKD 0.88â–²(0.69% Upside)
Action:reiterated
Date:09/07/26

The score is driven primarily by improving financial performance (stronger TTM revenue growth, sharply narrowed losses, low leverage, and positive operating/free cash flow), but it is held back by still-negative earnings and weakening TTM free cash flow growth. Technically, momentum is modestly positive in the short term (above 20-day DMA with positive MACD) but the longer-term trend remains pressured (below 100/200-day DMAs). Valuation is a headwind because profitability is not yet positive (negative P/E) and there is no dividend yield provided.

Positive Factors
Strong Revenue ReaccelerationThe sharp TTM revenue acceleration indicates stronger demand and improving commercial traction across the company’s digital pharmacy and healthcare platform. If sustained, this growth can expand the operating base, improve fixed-cost absorption, and support continued investment in fulfillment and online services.
Negative Factors
Earnings Remain NegativeAlthough losses have narrowed substantially, the company has not yet established positive earnings or a durable profit buffer. Continued negative earnings leave less capacity to absorb pricing, cost, or execution pressure, and make successful operating leverage essential for strengthening long-term financial resilience.

Dingdang Health Technology Group Ltd. (9886) vs. iShares MSCI Hong Kong ETF (EWH)

-40%-30%-20%-10%0%10%20%HK:9886-18.69%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.06B
Dividend Yield
―
Average Volume (3M)
749.79K
Price to Earnings (P/E)
-15.0
Beta (1Y)
1.11
Revenue Growth
8.73%
EPS Growth
80.38%
Country
Hong Kong
Employees
2,232
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Dingdang Health Technology Group Ltd. Business Overview & Revenue Model

Company Description

Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is base...

How the Company Makes Money

Dingdang Health Technology Group Ltd. primarily makes money by selling products and services through its integrated retail-pharmacy and internet-health platforms. Key revenue streams include: (1) Retail sales of pharmaceuticals and health products: r...

Dingdang Health Technology Group Ltd. Financial Statement Overview

Summary

Financials are improving but not yet fully proven: revenue re-accelerated sharply in TTM (~83% vs prior period shown), losses narrowed to ~1% of revenue and operations are near break-even, balance-sheet leverage is conservative (debt-to-equity ~0.17), and operating/free cash flow are positive in 2025 and TTM. Offsetting this, earnings remain negative, ROE is still negative, and TTM free cash flow growth turned negative, suggesting recent softening in cash conversion.

Income Statement

52Neutral

Balance Sheet

67Positive

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.97B4.89B4.67B4.86B4.33B3.68B
Gross Profit1.79B1.72B1.54B1.51B1.45B1.16B
EBITDA153.01M87.27M-78.90M-73.35M-191.11M-525.36M
Net Income-61.72M-49.02M-376.50M-225.81M-2.83B-1.58B
Balance Sheet
Total Assets2.84B2.84B2.63B3.06B3.30B2.95B
Cash, Cash Equivalents and Short-Term Investments1.13B1.12B1.22B1.33B1.35B1.55B
Total Debt261.79M281.81M152.61M140.21M163.14M4.81B
Total Liabilities1.31B1.16B952.45M1.03B1.10B5.54B
Stockholders Equity1.53B1.66B1.66B2.04B2.19B-2.61B
Cash Flow
Free Cash Flow94.47M122.54M-36.45M-25.82M-264.87M-408.32M
Operating Cash Flow116.64M154.59M-11.35M-5.24M-230.00M-372.99M
Investing Cash Flow446.89M-811.00M156.96M104.32M-353.42M306.63M
Financing Cash Flow-181.05M-109.18M-121.37M-130.54M232.90M1.27B

Dingdang Health Technology Group Ltd. Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.87

Price Trends

50DMA0.84Positive
100DMA0.84Positive
200DMA0.88Negative

Market Momentum

MACD0.01Positive
RSI53.52Neutral
STOCH66.95Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9886, the sentiment is Neutral. The current price of 0.87 is below the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.84, and below the 200-day MA of 0.88, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 53.52 is Neutral, neither overbought nor oversold. The STOCH value of 66.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9886.

Dingdang Health Technology Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:9886 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:6601HK:660174OutperformHKD 2.58B8.328.51%8.62%25.14%39.67%
HK:2367HK:236770OutperformHKD 20.63B10.7217.22%3.14%-9.65%-25.51%
HK:9886HK:988656NeutralHKD 1.06B-15.03-3.87%―8.73%80.38%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2138HK:213849NeutralHKD 651.87M-1.62-25.36%―-8.94%-140.82%
HK:0157HK:015745NeutralHKD 920.97M-16.03-12.81%―13.43%7.72%
HK:0399HK:039942NeutralHKD 231.21M-0.3653.52%―――

* Healthcare Sector Average

Performance Comparison

0%100%200%300%HK:9886HK:0399HK:0157HK:6601HK:2138HK:2367Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:9886 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:9886Dingdang Health Technology Group Ltd.0.87-0.22-20.18%
HK:0399Innovative Pharmaceutical Biotech 0.070.0114.06%
HK:0157Natural Beauty Bio-Technology 0.46-0.05-9.80%
HK:6601Cheerwin Group Limited1.94-0.15-7.06%
HK:2138EC Healthcare0.55-0.08-12.70%
HK:2367Giant Biogene Holding Co. Ltd.19.68-16.49-45.59%

Dingdang Health Technology Group Ltd. Corporate Events

Dingdang Health Posts Higher Loss but Near-Breakeven Adjusted Results in First Half 2026

Aug 21, 2026

Dingdang Health Technology Group Ltd. reported unaudited interim results for the six months ended June 30, 2026, showing modest revenue growth but widening headline losses. Revenue rose 3.5% year-on-year to RMB2.41 billion, while loss for the period...

Dingdang Health Sets August Board Meeting to Approve Interim Results and Consider Dividend

Aug 11, 2026

Dingdang Health Technology Group Ltd. has scheduled a board meeting for August 21, 2026, to review and approve the group’s interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider the po...

Dingdang Health Revamps Board with New Executive Director and Committee Changes

Jul 21, 2026

Dingdang Health Technology Group Ltd. has announced a board reshuffle effective July 21, 2026, with non-executive director Li Chuheng resigning to pursue other business engagements and stepping down from the remuneration and nomination committees. Th...

Dingdang Health Details Board and Committee Structure

Jul 21, 2026

Dingdang Health Technology Group Ltd. has outlined the composition of its board of directors, naming Chairman and President Yang Wenlong alongside five other executive directors and three independent non-executive directors. The announcement undersco...

Dingdang Health Technology Announces Company Secretary Resignation and Governance Continuity

Jun 26, 2026

Dingdang Health Technology Group Ltd. has announced the resignation of joint company secretary Liu Zhenxuan, effective June 26, 2026, as he plans to focus on other business engagements. The board noted that Liu has no disagreements with the directors...

Dingdang Health Wins Strong Shareholder Backing at Annual Meeting

Jun 23, 2026

Dingdang Health Technology Group Ltd. reported that all resolutions at its June 23 annual general meeting in Beijing were passed by shareholders via poll, including adoption of the 2025 audited financial statements and re-election of key executive, n...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 07, 2026